Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals,
Vaccines, Targeted Therapy And Immunosuppressants) - Global
Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
Published on January 2013

Report Summary

This report covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue.
The global market for liver diseases therapeutics is classified into seven drug class segments namely, anti-viral drugs, vaccines,
immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and chemotherapy with their estimated and forecasted
market size from 2012 to 2018, along with their compound annual growth rate.

This report also covers an in-depth competitive analysis for the market, taking into consideration some of the major market players.
The market players considered are: Abbott Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers
Squibb, Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company overview, financial overview, product
portfolio and recent developments is also provided in the report.

We have used secondary research for deriving our market numbers for each segment of the research report and further validated our
analysis with C-level executives of major companies operating in liver diseases therapeutics market through the means of primary
research to finally come up with our results. This research is specially designed to estimate and analyze the performance of liver
diseases therapeutics in a global scenario. This research provides in-depth analysis of liver diseases therapeutics market sales, trend
analysis by segments.

Table of Content

TABLE OF CONTENT

CHAPTER 1 PREFACE
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SIZE
3.3 COMPARATIVE ANALYSIS OF GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS, 2011 & 2018
3.4 LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
3.4.1 DRIVERS
3.4.1.1 Aging population inducing chronic liver diseases such as hepatitis and liver cancer
3.4.1.2 Increasing global prevalence of liver diseases
3.4.1.3 High unmet needs exist in the liver cancer therapeutics

Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Page 1/9
Forecast, 2012 - 2018 (From Slideshare)


3.4.1.4 Increased vaccination in emerging economies
3.4.2 LIVER DISEASE THERAPEUTICS MARKET DRIVERS IMPACT ANALYSIS
3.4.3 RESTRAINTS
3.4.3.1 Side-effects and risks
3.4.3.2 FDA approvals and other government regulations
3.4.3.3 Availability of alternate treatment procedures
3.4.4 LIVER DISEASE THERAPEUTICS MARKET RESTRAINTS IMPACT ANALYSIS
3.4.5 OPPORTUNITIES
3.4.5.1 Strong pipeline drugs
3.4.5.2 Emerging economies in Asia, Latin America and Eastern European countries
3.4.5.3 Consolidation opportunities in the healthcare industry
3.5 PORTER'S FIVE FORCES ANALYSIS FOR LIVER DISEASES THERAPEUTICS MARKET
3.5.1 BARGAINING POWER OF SUPPLIERS
3.5.2 BARGAINING POWER OF BUYERS
3.5.3 THREAT OF NEW ENTRANTS
3.5.4 THREAT OF SUBSTITUTES
3.5.5 COMPETITIVE RIVALRY

CHAPTER 4 LIVER DISEASES CLASSIFICATION AND THERAPY OPTIONS
4.1 ALCOHOL INDUCED LIVER DISEASE
4.1.1 OVERVIEW
4.1.2 EPIDEMIOLOGY
4.1.3 ETIOLOGY
4.1.4 SYMPTOMS
4.1.5 PATHOPHYSIOLOGY
4.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.1.6.1 Anabolic Steroids
4.1.6.2 Alcohol Abuse Drugs
4.2 AUTOIMMUNE LIVER DISORDER
4.2.1 AUTOIMMUNE HEPATITIS (AIH)
4.2.1.1 OVERVIEW
4.2.1.2 EPIDEMIOLOGY
4.2.1.3 ETIOLOGY
4.2.1.4 SYMPTOMS
4.2.1.5 PATHOPHYSIOLOGY
4.2.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.2.1.6.1 Antimetabolites
4.2.1.6.2 Corticosteroids
4.3 HEPATOCELLULAR CARCINOMA
4.3.1 OVERVIEW
4.3.2 EPIDEMIOLOGY
4.3.3 ETIOLOGY
4.3.4 SYMPTOMS
4.3.6.1 Chemotherapy
4.3.6.2 Targeted Therapy
4.4 NON-ALCOHOLIC FATTY LIVER DISEASE



4.4.1 OVERVIEW
4.4.2 EPIDEMIOLOGY
4.4.3 ETIOLOGY
4.4.4 SYMPTOMS
4.4.6.1 Gallstone solubilising drugs
4.5 VIRAL/HEPATITIS LIVER DISORDER
4.5.1 HEPATITIS A
4.5.1.1 OVERVIEW
4.5.1.3 ETIOLOGY
4.5.1.4 SYMPTOMS
4.5.1.6.1 Vaccines
4.5.1.6.2 Immunoglobulins
4.5.2 HEPATITIS B
4.5.2.1 OVERVIEW
4.5.2.3 ETIOLOGY
4.5.2.4 SYMPTOMS
4.5.2.6.1 Antiviral drugs
4.5.2.6.2 Immunoglobulins
4.5.2.6.3 Vaccines
4.5.3 HEPATITIS C
4.5.3.1 OVERVIEW
4.5.3.3 ETIOLOGY
4.5.3.4 SYMPTOMS
4.5.3.6.1 Antiviral drugs
4.5.4 HEPATITIS D
4.5.4.1 OVERVIEW
4.5.4.3 ETIOLOGY
4.5.4.4 SYMPTOMS
4.5.5 HEPATITIS E
4.5.5.1 OVERVIEW
4.5.5.3 ETIOLOGY
4.5.5.4 SYMPTOMS




CHAPTER 5 LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS
5.1 IMMUNOSUPPRESSANTS
5.1.1 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 ' 2018 (USD MILLION)
5.2 CHEMOTHERAPY DRUGS
5.2.1 GLOBAL CHEMOTHERAPY DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 ' 2018 (USD MILLION)
5.3 TARGETED THERAPY DRUGS
5.3.1 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 ' 2018 (USD MILLION)
5.4 VACCINES
5.4.1 GLOBAL VACCINES MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 ' 2018 (USD MILLION)
5.5 ANTI-VIRAL DRUGS
5.5.1 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 ' 2018 (USD MILLION)
5.6 IMMUNOGLOBULINS
5.6.1 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 ' 2018 (USD MILLION)
5.7 CORTICOSTERIODS
5.7.1 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 ' 2018 (USD MILLION)

CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 MARKET SHARE OF KEY PLAYERS IN LIVER DISEASES THERAPEUTICS MARKET BY DRUG CLASS
6.1.1 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASES
6.1.2 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES
6.1.3 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES
6.1.4 MARKET SHARE OF KEY PLAYERS FOR TARGETED THERAPY FOR LIVER DISEASES
6.1.5 NEW ENTRANTS (PHASE III)
6.1.6 COMPETITIVE STRATEGY BY KEY PLAYERS
6.1.6.1 Investments in R&D and clinical studies
6.1.6.2 Entering the emerging economies
6.1.6.3 Investing in different segments of the market
6.1.7 COMPETITIVE STRATEGY BY NEW ENTRANTS
6.1.8 AGREEMENTS AND COLLABORATIONS

CHAPTER 7 RECOMMENDATIONS
7.1 MARKET STRATEGY FOR SUCCESS
7.2 BARRIERS TO BE CONSIDERED

CHAPTER 8 COMPANY PROFILES
8.1 ABBOTT LABORATORIES
8.1.1 COMPANY OVERVIEW
8.1.2 FINANCIAL OVERVIEW
8.1.3 BUSINESS STRATEGIES
8.1.3.1 Significant R&D investments for new products development
8.1.3.2 Investing in emerging markets
8.1.3.3 Conducting clinical trials
8.1.4 PRODUCT PORTFOLIO
8.1.5 RECENT DEVELOPMENTS
8.2 ASTELLAS PHARMA INC.



8.2.3.1 Investing in emerging economies
8.2.3.2 Investing in research and development
8.3 BRISTOL-MYERS SQUIBB
8.3.3.1 Mergers, acquisitiosn and strategic development
8.4 GILEAD SCIENCES
8.4.3.1 Innovative new products
8.5 GLAXOSMITHKLINE PLC
8.5.3.1 Research and development investments
8.5.3.2 Delivering new products
8.6 F. HOFFMANN-LA ROCHE LTD
8.6.3.1 Strategic alliance initiative
8.7 MERCK & CO. INC
8.7.3.1 R&D initiatives
8.7.3.2 Strategic alliance
8.7.3.3 Corporate social responsibility and awareness
8.8 NOVARTIS AG



8.9 SANOFI S.A
8.9.3.1 Business Diversification
8.9.3.2 Research and development initiative
8.10 PFIZER INC.
8.11 TAKEDA PHARMACEUTICAL
8.11.3.1 Investing in emerging economies
8.12 VALEANT PHARMACEUTICALS
8.13 WATSON PHARMACEUTICALS, INC.
8.13.3.1 Investing in generic and biosimilar segments

LIST OF FIGURES



FIG. 1 GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS, 2011 (USD MILLION)
FIG. 2 LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION
FIG. 3 COMPARATIVE MARKET SHARE ANALYSIS OF GLOBAL LIVER DISEASE THERAPEUTICS MARKET, BY DRUG CLASS,
2011 & 2018
FIG. 4 PORTER'S FIVE FORCES ANALYSIS FOR THE LIVER DISEASES THERAPEUTICS MARKET
FIG. 5 PROGRESSION OF ALCOHOL INDUCED LIVER DISEASE IN HEAVY DRINKERS
FIG. 6 PROGRESSION OF HEPATOCELLULAR CANCER
FIG. 7 TWO-HIT CONCEPT OF NON-ALCOHOLIC FATTY LIVER DISEASE
FIG. 8 PATHOGENESIS OF HEPATITIS A VIRUS
FIG. 9 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 ' 2018 (USD MILLION)
FIG. 10 GLOBAL CHEMOTHERAPY MARKET FOR LIVER DISEASE THERAPEUTICS , 2010 ' 2018 (USD MILLION)
FIG. 11 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010' 2018 (USD MILLION)
FIG. 12 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 ' 2018 (USD MILLION)
FIG. 13 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 ' 2018 (USD MILLION)
FIG. 14 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 ' 2018 (USD MILLION)
FIG. 15 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASES, 2011 (%)
FIG. 16 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES, 2011 (%)
FIG. 17 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES, 2011 (%)
FIG. 18 ABBOTT LABORATORIES NET SALES, 2008-2011 (USD MILLION)
FIG. 19 ASTELLAS PHARMA INC. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 20 BRISTOL-MYERS SQUIBB ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 21 GILEAD SCIENCE ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 22 GLAXO SMITHKLINE ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 23 F. HOFFMANN-LA ROCHE LTD. ANNUAL SALES, 2007-2011 (USD MILLION)
FIG. 24 MERCK & CO, INC. ANNUAL REVENUE, 2007 ' 2011 (USD MILLION)
FIG. 25 NOVARTIS AG. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 26 SANOFI SA. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 27 PFIZER INC. ANNUAL REVENUE, 2009-2011 (USD MILLION)
FIG. 28 TAKEDA INC. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 29 VALEANT PHARMACEUTICAL ANNUAL REVENUE, 2008-2011 (USD MILLION)
FIG. 30 WATSON PHARMACEUTICALS INC., 2007-2011 (USD MILLION)

LIST OF TABLES

TABLE 1 GLOBAL LIVER DISEASES THERAPEUTICS MARKET: SNAPSHOT
TABLE 2 GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2010 - 2018
TABLE 3 IMPACT ANALYSIS OF DRIVERS
TABLE 4 IMPACT ANALYSIS OF RESTRAINTS
TABLE 5 PIPELINE DRUGS FOR LIVER DISEASES THERAPEUTICS (PHASE III)
TABLE 6 RECENT AGREEMENT AND COLLABORATION OF KEY PLAYERS


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressan
ts) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 4 595.00 Quantity: _____

Multi-User License--USD 7 595.00 Quantity: _____

Global Site--USD 10 595.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018

Recomendados

Recomendados

Más contenido relacionado

Destacado

Destacado (8)

Más de ReportLinker.com

Más de ReportLinker.com (20)

Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018